Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study

Nature Medicine

Volumn 25, Issue 7, 2019, Pages 1096-1103

  Depommier, Clara ^a   Everard, Amandine ^a   Druart, Céline ^a   Plovier, Hubert ^a   Van Hul, Matthias ^a   Vieira Silva, Sara ^b,c   Falony, Gwen ^b,c   Raes, Jeroen ^b,c   Maiter, Dominique ^a,d   Delzenne, Nathalie M ^a   de Barsy, Marie ^a,d   Loumaye, Audrey ^a,d   Hermans, Michel P ^a,d   Thissen, Jean Paul ^a,d   de Vos, Willem M ^e,f   Cani, Patrice D ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^d CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^e WAGENINGEN UNIVERSITY   (Netherlands)

^f UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; INSULIN; MICROBIAL PRODUCTS NOT CLASSIFIED ELSEWHERE; PLACEBO;

ADULT; AGED; AKKERMANSIA MUCINIPHILA; BODY MASS; BODY WEIGHT LOSS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; EXPLORATORY RESEARCH; FEASIBILITY STUDY; FEMALE; GLUCOSE METABOLISM; HIP CIRCUMFERENCE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULINEMIA; INTESTINE FLORA; INTRA-ABDOMINAL FAT; LETTER; LEUKOCYTE COUNT; LIVER DYSFUNCTION; MALE; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESE PATIENT; OBESITY; PERMEABILITY BARRIER; PILOT STUDY; PRIORITY JOURNAL; PROOF OF CONCEPT; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; WAIST CIRCUMFERENCE; DIETARY SUPPLEMENT; FECES; METABOLISM; MICROBIOLOGY; MIDDLE AGED; VERRUCOMICROBIA;

ADULT; AGED; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FECES; GASTROINTESTINAL MICROBIOME; HUMANS; INSULIN RESISTANCE; MIDDLE AGED; OBESITY; OVERWEIGHT; PILOT PROJECTS; VERRUCOMICROBIA;

EID: 85068458610     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/s41591-019-0495-2     Document Type: Article

References (49)

1. O’Neill, S. & O’Driscoll, L. Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. Obes. Rev. 16, 1–12 (2015).
2. Cani, P. D. et al. Microbial regulation of organismal energy homeostasis. Nat. Metab. 1, 34–46 (2019).
3. Brahe, L. K. et al. Specific gut microbiota features and metabolic markers in postmenopausal women with obesity. Nutr. Diabetes 5, e159 (2015).
4. Zhang, X. et al. Human gut microbiota changes reveal the progression of glucose intolerance. PLoS ONE 8, e71108 (2013).
5. Yassour, M. et al. Sub-clinical detection of gut microbial biomarkers of obesity and type 2 diabetes. Genome Med. 8, 17 (2016).
6. Li, J. et al. Gut microbiota dysbiosis contributes to the development of hypertension. Microbiome 5, 14 (2017).
7. Liu, R. et al. Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention. Nat. Med. 23, 859–868 (2017).
8. Dao, M. C. et al. Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. Gut 65, 426–436 (2016).
9. Cani, P. D. & de Vos, W. M. Next-generation beneficial microbes: the case of Akkermansia muciniphila. Front. Microbiol. 8, 1765 (2017).
10. Everard, A. et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc. Natl Acad. Sci. USA 110, 9066–9071 (2013).
11. Plovier, H. et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat. Med. 23, 107–113 (2017).
12. Everard, A. et al. Intestinal epithelial N-acylphosphatidylethanolamine phospholipase D links dietary fat to metabolic adaptations in obesity and steatosis. Nat. Commun. 10, 457 (2019).
13. Atkin, S. L. et al. Effect of dipeptidyl peptidase-4 inhibitors on circulating tumor necrosis factor-α concentrations: a systematic review and meta-analysis of controlled trials. J. Diabetes Complicat. 31, 1458–1464 (2017).
14. Akoumianakis, I. & Antoniades, C. Dipeptidyl peptidase IV inhibitors as novel regulators of vascular disease. Vascul. Pharmacol. 96–98, 1–4 (2017).
15. Olivares, M. et al. The potential role of the dipeptidyl peptidase-4-like activity from the gut microbiota on the host health. Front. Microbiol. 9, 1900 (2018).
16. Veronelli, A. et al. White blood cells in obesity and diabetes: effects of weight loss and normalization of glucose metabolism. Diabetes Care 27, 2501–2502 (2004).
17. Ohshita, K. et al. Elevated white blood cell count in subjects with impaired glucose tolerance. Diabetes Care 27, 491–496 (2004).
18. Gu, Y. et al. White blood cells count as an indicator to identify whether obesity leads to increased risk of type 2 diabetes. Diabetes Res. Clin. Pract. 141, 140–147 (2018).
19. Zhang, H. et al. White blood cell subtypes and risk of type 2 diabetes. J. Diabetes Complicat. 31, 31–37 (2017).
20. Twig, G. et al. White blood cells count and incidence of type 2 diabetes in young men. Diabetes Care 36, 276–282 (2013).
21. Shen, J. et al. Low-density lipoprotein receptor signaling mediates the triglyceride-lowering action of Akkermansia muciniphila in genetic-induced hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. 36, 1448–1456 (2016).
22. −/− mice. Circulation 133, 2434–2446 (2016).
23. Ras, R. T. et al. Consumption of plant sterol-enriched foods and effects on plasma plant sterol concentrations—a meta-analysis of randomized controlled studies. Atherosclerosis 230, 336–346 (2013).
24. Wannamethee, S. G., Shaper, A. G., Lennon, L. & Whincup, P. H. Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care 28, 2913–2918 (2005).
25. Rantala, A. O. et al. Gamma-glutamyl transpeptidase and the metabolic syndrome. J. Intern. Med. 248, 230–238 (2000).
26. Lim, J. S., Lee, D. H., Park, J. Y., Jin, S. H. & Jacobs, D. R. Jr. A strong interaction between serum γ-glutamyltransferase and obesity on the risk of prevalent type 2 diabetes: results from the Third National Health and Nutrition Examination Survey. Clin. Chem. 53, 1092–1098 (2007).
27. Fraser, A. et al. Alanine aminotransferase, γ-glutamyltransferase, and incident diabetes: the British Women’s Heart and Health Study and meta-analysis. Diabetes Care 32, 741–750 (2009).
28. Hänninen, A. et al. Akkermansia muciniphila induces gut microbiota remodelling and controls islet autoimmunity in NOD mice. Gut 67, 1445–1453 (2018).
29. Grander, C. et al. Recovery of ethanol-induced Akkermansia muciniphila depletion ameliorates alcoholic liver disease. Gut 67, 891–901 (2018).
30. Wu, W. et al. Protective effect of Akkermansia muciniphila against immune-mediated liver injury in a mouse model. Front. Microbiol. 8, 1804 (2017).
31. Harte, A. L. et al. Elevated endotoxin levels in non-alcoholic fatty liver disease. J. Inflamm. (Lond.) 7, 15 (2010).
32. Cani, P. D. et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56, 1761–1772 (2007).
33. Miele, L. et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 49, 1877–1887 (2009).
34. Lassenius, M. I. et al. Bacterial endotoxin activity in human serum is associated with dyslipidemia, insulin resistance, obesity, and chronic inflammation. Diabetes Care 34, 1809–1815 (2011).
35. Allin, K. H. et al. Aberrant intestinal microbiota in individuals with prediabetes. Diabetologia 61, 810–820 (2018).
36. Wu, H. et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat. Med. 23, 850–858 (2017).
37. Dao, M. C. et al. Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. Gut 65, 426–436 (2016).
38. Scherbaum, W. A. et al. Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes. Metab. 10, 675–682 (2008).
39. Rosenstock, J., Rigby, S. P., Ford, D. M., Tao, B. & Chou, H. S. The glucose and lipid effects of colesevelam as monotherapy in drug-naïve type 2 diabetes. Horm. Metab. Res. 46, 348–353 (2014).
40. Kim, S. G. et al. Efficacy and safety of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 24-weeks: a multicenter, randomized, double-blind, parallel-group, placebo controlled trial. PLoS ONE 9, e92843 (2014).
41. Werner, M., Tönjes, A., Stumvoll, M., Thiery, J. & Kratzsch, J. Assay-dependent variability of serum insulin levels during oral glucose tolerance test: influence on reference intervals for insulin and on cut-off values for insulin sensitivity indices. Clin. Chem. Lab. Med. 46, 240–246 (2008).
42. Borza, D. et al. Influence of assay-dependent variability of serum insulin levels on insulin sensitivity indices. Clin. Chem. Lab. Med. 46, 1655–1656 (2008).
43. Wallace, T. M., Levy, J. C. & Matthews, D. R. Use and abuse of HOMA modeling. Diabetes Care 27, 1487–1495 (2004).
44. Dennis, J. M. et al. Precision medicine in type 2 diabetes: clinical markers of insulin resistance are associated with altered short- and long-term glycemic response to DPP-4 inhibitor therapy. Diabetes Care 41, 705–712 (2018).
45. Vandeputte, D. et al. Quantitative microbiome profiling links gut community variation to microbial load. Nature 551, 507–511 (2017).
46. Callahan, B. J. et al. DADA2: high-resolution sample inference from Illumina amplicon data. Nat. Methods 13, 581–583 (2016).
47. Wang, Q., Garrity, G. M., Tiedje, J. M. & Cole, J. R. Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl. Environ. Microbiol. 73, 5261–5267 (2007).
48. Oksanen, J. B. et al. vegan: community ecology package. R package version 2.5-3 (2018).
49. Gloor, G. B. & Reid, G. Compositional analysis: a valid approach to analyze microbiome high-throughput sequencing data. Can. J. Microbiol. 62, 692–703 (2016).